{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:02:43Z","timestamp":1791234163527,"version":"4.1.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"11-12","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B (HBV) infection affects 4%\u201314% of people with HIV infection in Turkey. Tenofovir alafenamide (TAF) is highly effective in treatment of HIV infection. While it is active against HBV, data on the use in HIV-HBV co-infection are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We analyzed the efficacy of tenofovir disoproxil fumarate (TDF)- and TAF-containing regimens in patients with HIV-HBV co-infection from six centers in Istanbul, Turkey. The results of the cohort of 36 months were presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      259 patients were enrolled: 146 and 113 were receiving TAF- and TDF-containing regimens respectively. Baseline characteristics were comparable except TAF-containing group was older; had higher CD4 cell count and lower rate of CD4 count \u2264200 cells\/\u03bcL. Baseline HIV-RNA were 8.2 log copies\/mL and 6.8 log in TAF- and TDF-containing groups, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      = .059) and HBV-DNA levels were 8.1 log IU\/mL in both groups. Thirty-eight and 39% of the patients were HBeAg-positive. After 36 months, undetectable HBV-DNA was noted in 88% and 87%, and undetectable HIV-RNA in 85% and in 83% of TAF and TDF-containing groups, respectively. The increase in mean CD4 cell was significant in both groups: \u0394 = 311 cells\/\u03bcL in TAF- and \u0394 = 393 cells\/\u03bcL in TDF-containing groups. Rates of HBeAg loss (63% vs 57%), HBeAg seroconversion (35% vs 29%), HBsAg loss (29% vs 27%), and HBsAg seroconversion (23% vs 16%) were comparable at 36 months of therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-life study showed that both TAF- and TDF-containing regimens are effective in co-infected patients. The rates of HBsAg loss seemed higher than those in HBV-monoinfected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624251352345","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T17:28:38Z","timestamp":1750267718000},"page":"857-862","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of tenofovir alafenamide- or tenofovir disoproxil fumarate-containing regimens in adults with treatment-na\u00efve HIV-hepatitis B co-infection"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-2825","authenticated-orcid":false,"given":"Fehmi","family":"Tabak","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Y\u0131ld\u0131z Sevgi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Zerdali","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Furkan","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-3006","authenticated-orcid":false,"given":"Hayat","family":"Kumbasar Karaosmano\u011flu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Bakirk\u00f6y Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha","family":"Meri\u00e7 Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Bezmi Alem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Gunduz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Basaksehir Cam Sakura City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsen","family":"\u00d6nc\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nci Yilmaz","family":"Nakir","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1465-3283","authenticated-orcid":false,"given":"Esra","family":"Canpolat \u00dcnl\u00fc","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Bakirk\u00f6y Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Altunta\u015f Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Basaksehir Cam Sakura City Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-6087","authenticated-orcid":false,"given":"Bilgul","family":"Mete","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190149"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41124-017-0030-3"},{"key":"e_1_3_4_4_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adultand-adolescent-arv (Accessed November 17, 2024)."},{"key":"e_1_3_4_5_2","unstructured":"DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2022."},{"key":"e_1_3_4_6_2","unstructured":"EACS. European AIDS clinical society guidelines. 2022."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002223"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30421-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16788"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05125-22"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002429"},{"key":"e_1_3_4_12_2","first-page":"473","article-title":"Brief report: effect of antiretroviral switch from tenofovir disoproxil fumarate to tenofovir alafenamide on alanine aminotransferase, lipid profiles, and renal function in HIV\/HBV-coinfected individuals in a nationwide Canadian study","volume":"86","author":"Sarowar A","year":"2021","unstructured":"Sarowar A, Coffin CS, Fung S, et al. Brief report: effect of antiretroviral switch from tenofovir disoproxil fumarate to tenofovir alafenamide on alanine aminotransferase, lipid profiles, and renal function in HIV\/HBV-coinfected individuals in a nationwide Canadian study. J Acquir Immune Defic Syndr 2021; 86: 473\u2013481.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_3_4_13_2","first-page":"368","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/ emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients","volume":"91","author":"Huang YS","year":"2022","unstructured":"Huang YS, Cheng CY, Liou BH, et al. Efficacy and safety of elvitegravir\/cobicistat\/ emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients. J Acquir Immune Defic Syndr 2022; 91: 368\u2013372.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00151-0"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.028"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286254"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.4274\/vhd.galenos.2020.2019.0043"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v21i4.16"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01601.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068152"},{"key":"e_1_3_4_22_2","first-page":"65","article-title":"Evaluation of HBsAg clearance in patients with hepatitis B","volume":"12","author":"Konya P","year":"2022","unstructured":"Konya P, Demirturk N. Evaluation of HBsAg clearance in patients with hepatitis B. Eurasian J Hepatogastroenterol 2022; 12: 65\u201368.","journal-title":"Eurasian J Hepatogastroenterol"},{"key":"e_1_3_4_23_2","first-page":"47","article-title":"Evaluation of tenofovir disoproxil fumarate in patients with hepatitis B","volume":"10","author":"Taskin MC","year":"2022","unstructured":"Taskin MC, Uyanikoglu A, Cindoglu C. Evaluation of tenofovir disoproxil fumarate in patients with hepatitis B. Infect Dis Clin Microbiol 2022; 10: 47\u201354.","journal-title":"Infect Dis Clin Microbiol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_3_4_25_2","first-page":"324","article-title":"3-year treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"Hou J","year":"2021","unstructured":"Hou J, Ning Q, Duan Z, et al. 3-year treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China. J CLin Transl Hepatol 2021; 9: 324\u2013334.","journal-title":"J CLin Transl Hepatol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13071341"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis439"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251352345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624251352345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251352345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:46:49Z","timestamp":1777675609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624251352345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":26,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/09564624251352345"],"URL":"https:\/\/doi.org\/10.1177\/09564624251352345","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}